PROTAGONIST THERAPEUTICS INC

NASDAQ: PTGX (Protagonist Therapeutics, Inc.)

Kemas kini terakhir: 10 Apr, 7:33PM

40.89

-1.68 (-3.95%)

  • 1H -3.95%
  • 5H -8.09%
  • 1B -9.19%
  • 6B -5.28%
  • Tahun Ke Tarikh 4.90%
  • 1T 39.46%
  • 5T 155.56%
Penutupan Terdahulu 42.57
Buka 41.44
Jumlah Dagangan 1,577,271
Purata Dagangan (3B) 1,083,501
Modal Pasaran 2,610,577,152
Harga / Pendapatan (P/E TTM) 9.67
Harga / Pendapatan (P/E Ke hadapan) 26.39
Harga / Jualan (P/S) 6.82
Harga / Buku (P/B) 4.18
Julat 52 Minggu
24.22 (-40%) — 60.60 (48%)
Tarikh Pendapatan 5 May 2025 - 9 May 2025
Margin Keuntungan 63.34%
Margin Operasi (TTM) 74.30%
EPS Cair (TTM) 4.23
Pertumbuhan Hasil Suku Tahunan (YOY) 184.40%
Pertumbuhan Pendapatan Suku Tahunan (YOY) 381.70%
Jumlah Hutang/Ekuiti (D/E MRQ) 1.61%
Nisbah Semasa (MRQ) 12.48
Aliran Tunai Operasi (OCF TTM) 184.15 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 65.11 M
Pulangan Atas Aset (ROA TTM) 28.66%
Pulangan Atas Ekuiti (ROE TTM) 54.39%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Menurun
Biotechnology (Global) Bercampur Menurun
Stok Protagonist Therapeutics, Inc. Menaik Menaik

AISkor Stockmoo

1.0
Konsensus Penganalisis 1.5
Aktiviti Orang Dalam NA
Volatiliti Harga 2.0
Purata Bergerak Teknikal 2.5
Osilator Teknikal -2.0
Purata 1.00

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
PTGX 3 B - 9.67 4.18
TGTX 5 B - 134.56 26.86
ADMA 5 B - 23.79 15.26
RYTM 3 B - - 190.80
VKTX 3 B - - 2.88
VCEL 2 B - 834.60 6.53

Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enables the discovery and development of novel constrained peptide-based drug candidates to address medical needs. Its pipeline products include Rusfertide (PTG-300) and JNJ-2113.
Sektor Healthcare
Industri Biotechnology
Gaya Pelaburan Small Growth
% Dimiliki oleh Orang Dalam 1.37%
% Dimiliki oleh Institusi 107.63%
85.9085.9068.2068.2050.5050.5032.8032.8015.1015.10Harga Sasaran MedianQ1 '22Q1 '22Q2 '22Q2 '22Q3 '22Q3 '22Q4 '22Q4 '22Q1 '23Q1 '23Q2 '23Q2 '23Q3 '23Q3 '23Q4 '23Q4 '23Q1 '24Q1 '24Q2 '24Q2 '24Q3 '24Q3 '24Q4 '24Q4 '24Q1 '25Q1 '25Q2 '25Q2 '25
Julat 52 Minggu
24.22 (-40%) — 60.60 (48%)
Julat Harga Sasaran
38.00 (-7%) — 80.00 (95%)
Tinggi 80.00 (HC Wainwright & Co., 95.65%) Beli
Median 70.00 (71.19%)
Rendah 38.00 (Goldman Sachs, -7.07%) Pegang
Purata 64.86 (58.62%)
Jumlah 6 Beli, 1 Pegang
Harga Purata @ Panggilan 48.56
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
HC Wainwright & Co. 10 Apr 2025 80.00 (95.65%) Beli 40.89
11 Mar 2025 80.00 (95.65%) Beli 59.76
Wedbush 28 Mar 2025 70.00 (71.19%) Beli 48.88
BMO Capital 11 Mar 2025 72.00 (76.08%) Beli 59.76
Truist Securities 11 Mar 2025 76.00 (85.86%) Beli 59.76
Citizens Capital Markets 10 Mar 2025 61.00 (49.18%) Beli 55.95
JP Morgan 04 Mar 2025 57.00 (39.40%) Beli 38.66
Goldman Sachs 24 Feb 2025 38.00 (-7.07%) Pegang 36.00

Tiada data dalam julat masa ini.

  • 3M
Tarikh Jenis Butiran
09 May 2025 Pengumuman Protagonist Announces Icotrokinra Phase 3 Data on Difficult-to-Treat Scalp and Genital Psoriasis and Preclinical Data on PN-881 Presented at the Society for Investigative Dermatology Annual Meeting
06 May 2025 Pengumuman Protagonist Reports First Quarter 2025 Financial Results and Provides Corporate Update
23 Apr 2025 Pengumuman Protagonist Therapeutics Announces Plenary Presentation on VERIFY Phase 3 Study with Rusfertide at ASCO 2025
16 Apr 2025 Pengumuman Protagonist Therapeutics Reports Granting of Inducement Award
10 Apr 2025 Pengumuman Icotrokinra Results Show 75% of Adolescents with Plaque Psoriasis Achieved Completely Clear Skin and Demonstrate Favorable Safety Profile with a Once Daily Pill
18 Mar 2025 Pengumuman Protagonist Therapeutics Named to Fast Company's Annual List of the World's Most Innovative Companies of 2025
10 Mar 2025 Pengumuman Protagonist Reports Positive Top Line Results From Phase 2b Study of Icotrokinra Showing Potential to Transform the Treatment Paradigm for Patients With Ulcerative Colitis
08 Mar 2025 Pengumuman Icotrokinra Clinical Study Results Demonstrate Its Potential to Shift Treatment Paradigm and Set a New Standard for Treatment in Plaque Psoriasis
03 Mar 2025 Pengumuman Protagonist and Takeda Announce Positive Topline Results from Phase 3 VERIFY Study of Rusfertide in Patients with Polycythemia Vera
21 Feb 2025 Pengumuman Protagonist Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
47.7347.7346.1946.1944.6544.6543.1043.1041.5641.56Apr 23Apr 23Apr 24Apr 24Apr 25Apr 25Apr 28Apr 28Apr 29Apr 29Apr 30Apr 30May 1May 1May 2May 2

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

10010075755050252500RSI (14H)
-0.000-0.000-0.100-0.100-0.200-0.200-0.300-0.300-0.400-0.400MACD (12, 26, 9)

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda